Aptevo Therapeutics Inc. APVO
Aptevo Therapeutics Inc. (Nasdaq: APVO) is an oncology drug developer. Its lead program, mipletamig (APVO436), is in Phase 1 for frontline acute myeloid leukemia (AML), in combination with venetoclax + azacitidine. Its next catalyst on record is mipletamig: Aptevo expects to complete the current RAINIER study by year-end 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: mipletamig — Aptevo expects to complete the current RAINIER study by year-end 2026. (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| mipletamig (CD123xCD3 T cell engager) | frontline AML (RAINIER Phase 1b/2, part one dose optimization) | antibody | Phase 1 |
| ALG.APV-527 (4-1BB x 5T4) | multiple 5T4-expressing solid tumors (Phase 1 dose escalation completed) | antibody | Phase 1 |
| APVO451 | solid tumors (nectin-4 trispecific), IND-enabling | antibody | Pre-clinical |
| APVO603 | oncology (4-1BB/OX40 preclinical) | antibody | Pre-clinical |
| APVO711 | oncology | antibody | Pre-clinical |
| APVO442 | oncology (PSMA) | antibody | Pre-clinical |
| APVO455 | oncology | antibody | Pre-clinical |
| APVO452 | oncology | antibody | Pre-clinical |
Recent results and decisions
- Nov 5, 2026positive Aptevo reports substantial reduction in infusion-related reactions with refined mipletamig priming-dose regimen in the ongoing RAINIER Phase 1b study.
Successive refinements to the priming-dose regimen have substantially reduced infusion-related reactions (IRRs) during initial treatment.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.